

10/573354

1AP20R03'd AGT/PTO 24 MAR 2006

PATENT
Attorney Docket No. 059742-5002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Richard M. Wright <i>et al.</i>)	
)	
U.S. National Phase of: PCT/US2004/031478)	Group Art Unit: <i>Unassigned</i>
)	
International Filing Date: September 27, 2004)	Examiner: <i>Unassigned</i>
)	
Date of Entry into U.S. National Stage: March 24, 2006)	
)	
For: Methods for Modulating Inflammatory)	
Reactions by Modulating Xanthine)	
Oxidoreductase Activity)	

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. 1.97(b)

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 forms. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

Copies of the listed documents are attached. The present application is a U.S. National Phase Application of International Patent Application PCT/US2004/031478, filed September 27, 2004 and published as WO 2005/030138 A2. Documents 1-4 were cited in the International Search Report which issued in International Patent Application PCT/US2004/031478. Applicants respectfully request that the Examiner consider the listed documents and evidence for consideration by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Dated: **March 24, 2006**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP
(Gregory T. Lowen)
Gregory Lowen Reg. No. 46,882
for Sally P. Teng, Ph.D.
Registration No. 45,397

